Mindray Medical International Announces Third Quarter 20...(net segment revenues in the third quarte...)

Growth in the patient monitoring segment was led by increased brand recognition in international markets as well as a healthier domestic environment compared to the third quarter 2006. The company's high-end BeneView series also experienced strong performance both domestically and internationally.

Diagnostic Laboratory Instruments: Diagnostic laboratory instrument segment revenues increased 64.5% to RMB186.3 million (US$24.9 million) from RMB113.3 million in the third quarter 2006. The diagnostic laboratory instrument segment contributed 33.0% of total net segment revenues in the third quarter 2007.

The diagnostic laboratory instrument segment enjoyed exceptional growth during the third quarter. Domestically, revenues were boosted by increased government spending on rural healthcare development. Expanding international market penetration and demand for new products such as the BS-400 and BC-5500 increased segment growth during the third quarter 2007.

Ultrasound Imaging Systems: Ultrasound imaging system segment revenues increased 66.2% to RMB162.2 million (US$21.7 million) from RMB97.6 million in the third quarter 2006. The ultrasound imaging system segment contributed 28.7% as a percentage of total net segment revenues in the third quarter 2007.

Government tender activity made a significant contribution to ultrasound growth during the third quarter 2007 compared to the same period a year ago. Demand for color ultrasound machines remained strong both domestically and internationally.

The company also plans to launch several products in the fourth quarter of 2007, including the M5, a portable color ultrasound machine, the BS-100, a biochemistry analyzer targeted for rural healthcare clinics in China, the DC-3, a color ultrasound machine, an EX55 and EX65, which are both compact anesthesia machines available domestically upon release and internationally in March 2008 and the BC-5300, a
'/>"/>